Absstract of: WO2022194039A1

A peripheral blood TCR marker for acute B lymphocytic leukemia, and a detection kit thereof and the use thereof. The peripheral blood TCR marker for acute B lymphocytic leukemia comprises at least one of proteins having sequences as shown in SEQ ID NOs.1-100. The method is based on a high-throughput sequencing method, and comprises: only collecting a small amount of peripheral blood, extracting RNA, establishing an immune spectrum library by means of treating a sample, then performing high-throughput sequencing and TCR data analysis to firstly determine the characteristic TCR sequence in the peripheral blood from a subject with acute B lymphocytic leukemia, and then comparing the detection result of a sample to be subjected to detection with the characteristic TCR sequence, thereby determining whether the subject suffers from acute B lymphocytic leukemia. The method can be used to simultaneously compare a large number of the specific TCR sequences of acute B lymphocytic leukemia, has a higher specificity and accuracy compared with the detection of one or several markers alone, thereby improving the efficiency of diagnosis.

Absstract of: WO2022194036A1

A peripheral blood TCR marker for classical Hodgkin lymphoma, a detection kit therefor, and an application thereof. The marker comprises at least one of proteins of which sequences are as shown in SEQ ID NOs. 1-100. On the basis of a high-throughput sequencing method, only a small amount of peripheral blood needs to be used, RNA is extracted, and an immune map library is established by treating a sample; then by means of high-throughput sequencing and TCR data analysis, a characteristic TCR sequence in the peripheral blood of classical Hodgkin lymphoma is determined first, and then a test result of a sample to be tested is compared with the characteristic TCR sequence, so as to determine whether a patient suffers from classical Hodgkin lymphoma. A huge number of specific TCR sequences of classical Hodgkin lymphoma can be compared at the same time, and compared with separate detection of one or more markers, the present invention has higher specificity and accuracy, and improves diagnosis efficiency.

Absstract of: WO2022194033A1

A peripheral blood TCR marker for diffuse large B-cell lymphoma, and a detection kit and use therefor. The marker comprises at least one among proteins having sequences shown in SEQ ID NO. 1-100. According to the high-throughput sequencing method: only requiring a small amount of peripheral blood, extracting RNA is extracted, establishing an immune map library by means of processing samples, then carrying out high-throughput sequencing and TCR data analysis, first determining a characteristic TCR sequence in the peripheral blood of the diffuse large B-cell lymphoma, and then comparing a test result of a sample to be tested with the characteristic TCR sequence, so as to determine whether diffuse large B cell lymphoma exists. The present solution compares a large number of diffuse large B cell lymphoma specific TCR sequences at the same time, and compared with separately detecting one or more markers, has higher specificity and accuracy, and improves diagnosis efficiency.

Absstract of: WO2022197690A1

This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a heteroaryl substituted oxadiazole structure which function as non-hydroxamate histone deacetylase 6 (HDAC6) inhibitors, and their use as therapeutics for the treatment of metabolic disorders (e.g., obesity, Diabetes), neurological disorders (e.g., Alzheimer's disease, Parkinson disease, Huntington disease), cancer (e.g., multiple myeloma, biliary tract cancer, non-small cell lung cancer, chronic lymphocytic leukemia) and other conditions related to HDAC6 activity (e.g., Rett syndrome (RTT), inherited retinal disorders (IRDS), idiopathic pulmonary fibrosis (IPF), and Charcot-Marie-Tooth disease (CMT)).

Absstract of: WO2022197934A1

Methods and materials for identifying and treating mammals (e.g., humans) having multiple myeloma (MM) are provided herein. For example, this document provides methods and materials that can be used to identify and treat mammals having advanced stage MM, and/or having MM that is resistant to treatment with immunomodulatory drugs (IMiDs) and/or proteasome inhibitors (PIs).

Absstract of: US2022298251A1

The present invention relates to antibodies that specifically bind to the BAFF receptor (BAFFR). The invention more specifically relates to specific antibodies that are BAFFR antagonists with in vivo B cell depleting activity and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by killing or depleting B cells, such as systemic lupus erythematosus or rheumatoid arthritis or other autoimmune diseases or lymphomas, leukemias and myelomas.

Absstract of: US2022296607A1

A method and medicament comprising 4,4,4-trifluoro-N-[(IS)-2-[[(7S)-5-(2-hydroxyethyl)-6-oxo-7H-pyrido[2,3-d][3]benzazepin-7-yl]amino]-1-methyl-2-oxo-ethyl]butanamide or a pharmaceutically acceptable salt or hydrate thereof for treating aggressive peripheral T-cell lymphoma is provided.

Absstract of: US2022298578A1

The invention relates to a method for predicting the prognosis of a patient suffering from a B-cell lymphoma, through the detection of the status of activation of the RelB protein, in a biological sample of said patient. The inventors indeed identified an associated gene expression signature in the biological sample. Some genes from said signature are over-expressed and other are under-expressed and allow detecting RelB activation and predicting a worse prognosis in B-cell lymphoma.

Absstract of: WO2022197933A1

The invention provides compositions and methods useful in characterizing and/or treating classical Hodgkin's Lymphoma and/or primary mediastinal B-cell lymphoma (PMBL). In embodiments, the characterization is carried out using a biological sample comprising circulating tumor DNA (ctDNA) from a subject.

Absstract of: WO2022197776A1

The invention provides compositions and methods useful for mobilizing populations of hematopoietic stem and progenitor cells within a donor, such as a donor with multiple myeloma, as well as for determining whether samples of mobilized cells are suitable for release for ex vivo expansion and/or therapeutic use. In accordance with the compositions and methods described herein, mobilized hematopoietic stem and progenitor cells can be withdrawn from a patient with multiple myeloma for performing an autologous stem cell transplant to treat the patient's multiple myeloma.

Absstract of: WO2022195118A1

The present invention concerns a postbiotic composition comprising at least one postbiotic and at least one bacteriocin and/or endolysin preferably formulated, and a postbiotic composition comprising at least one postbiotic and at least one bacteriocin and/or endolysin for use in the treatment of cutaneous T-cell lymphoma (CTCL) in a subject, wherein said postbiotic is preferably a microbial lysate, preferably obtained from microorganisms heterologously expressing said at least one bacteriocin and/or endolysin and wherein said at least one postbiotic and said at least one bacteriocin and/or endolysin have a synergistic effect in the treatment of CTCL in said subject.

Absstract of: WO2022195073A1

The present invention relates to the filed of immunotherapy, in particular, of lymphoproliferative disorders associated with abnormal proliferation of HLA-DR+ cells, e.g., malignancies of the hematopoietic and lymphoid tissues. The invention provides pharmaceutical compositions useful for, e.g., adoptive T cell therapy or T cell receptor (TCR) gene therapy or such disorders, as well as novel expression vectors, host cells and y8 (gamma/delta) TCR constructs. In particular, the inventors have identified γδ (gamma/delta) TCR constructs that can specifically bind to HLA-DR. In addition to host cells engineered to express such constructs that can be used for therapeutic as well as diagnostic purposes, soluble TCR constructs are provided, which can, e.g., be used in a method of detecting HLA-DR+ cells, e.g., in vitro as well as bispecific constructs that can be therapeutically used.

Absstract of: WO2022194067A1

Disclosed in the present invention are an anti-BAFFR antibody or an antigen-binding fragment thereof, a use thereof, and a pharmaceutical composition. The anti-BAFFR antibody provided by the present invention can specifically bind to BAFFR, block the BAFFR-BAFF signaling pathway, clear hyperproliferative B lymphocytes, and inhibit the growth of the B cells. The problem of drug resistance of existing drugs for treating B cell lymphoma is effectively solved.

Absstract of: EP4059955A1

The present invention relates to the filed of immunotherapy, in particular, of lymphoproliferative disorders associated with abnormal proliferation of HLA-DR+ cells, e.g., malignancies of the hematopoietic and lymphoid tissues. The invention provides pharmaceutical compositions useful for, e.g., adoptive T cell therapy or T cell receptor (TCR) gene therapy or such disorders, as well as novel expression vectors, host cells and γδ (gamma/delta) TCR constructs. In particular, the inventors have identified γδ (gamma/delta) TCR constructs that can specifically bind to HLA-DR. In addition to host cells engineered to express such constructs that can be used for therapeutic as well as diagnostic purposes, soluble TCR constructs are provided, which can, e.g., be used in a method of detecting HLA-DR+ cells, e.g., in vitro as well as bispecific constructs that can be therapeutically used.

Absstract of: EP4060042A1

Provided is a promoter having high activity in an activated T-cell. The promoter comprises, from 5'-end to 3'-end, a CMV enhancer, an IFNγ promoter, and a long terminal repeat sequence from human T-cell leukemia virus that are connected in sequence. The promoter exhibits greater activity in an activated immune cell than the existing promoters and is low in activity or inactive in other non-immune cells.

Absstract of: WO2022192916A1

The disclosure provides methods and materials for detecting endogenous IgA antibodies to one or more, or all, of OmpC (ACA), Ki67 (AKiA), TK1, integrin (AINTA) and keratin (AKERA), which are useful to diagnose and distinguish chronic enteropathies, e.g. gastrointestinal neoplasms, e.g., gastrointestinal lymphoma, and, inflammatory conditions, e.g. inflammatory bowel disease, in felines.

Absstract of: WO2022191724A1

The invention concerns a mix of the following phytocompounds: curcumin, genistein, resveratrol, quercetin applied to enhance cytotoxic activity in the treatment of acute lymphoblastic leukemias.

Absstract of: AU2022204792A1

-75 Provided is an active ingredient of a pharmaceutical composition for treating myeloma. Specifically, provided is an antibody whose epitope is present in the region of the amino acid 5 residue positions 20 to 109 of human integrin B7.

Absstract of: US2022289756A1

The invention provides small molecule heteroaromatic compounds that are ATP-competitive tyrosine kinase inhibitors displaying a significant inhibitory potency towards resistant T315I ABL mutants. The compounds of the invention find a useful application in the treatment of BCR-ABL inhibitor resistant diseases, such as imatinib resistant chronic myelogenous leukemia.

Absstract of: US2022289841A1

The present disclosure is directed to antibodies binding to CD22-Del.ex5-6 protein and methods of using such antibodies to treat cancers that express or overexpress CD22-Del.ex5-6 protein. Specifically, the disclosure provides a method of treating cancer comprising contacting a cancer cell in a subject with an antibody or antibody derivative that binds selectively to CD22-Del.ex5-6 protein, or to a peptide having the sequence of QLNVKHPPKKVTTVIQNP (SEQ ID NO: 1).

Absstract of: US2022288217A1

Provided herein are small molecules that bind to ASH1L and inhibit ASH1L activity, and methods of use thereof for the treatment of disease, including acute leukemia, solid cancers and other diseases dependent on activity of ASH1L.

Absstract of: US2022288040A1

Acute myeloid leukemia (AML) are heterogeneous malignancies arising from the multistep transformation of bone marrow immature cells. The inventors showed that RAS pathway mutations were detected in 40% of FLT3- and NPM1-unmutated AML cases and correlated with higher white blood cell count, blast cell percentage and reduced survival after intensive therapy. Building on genetic models of RAS activation, they highlighted the leukemogenic potential of RAS pathway alterations, and the efficacy and limitations of MEK inhibitors in this context. From high-content chemical screens, the inventors unraveled pyrvinium pamoate—an anthelminthic drug approved in human patients—as displaying a preferential cytotoxicity against RAS activated cells. This potential clinical candidate demonstrated a robust synergistic activity with the MEK inhibitor trametinib, including in primary samples from AML patients. Together the data suggest that RAS pathway altered cases may represent a specific AML subtype, in which the anti-leukemic molecule pyrvinium pamoate may represent a new promising therapeutic strategy.

Absstract of: US2022288072A1

The compound of formula (1a) wherein p is 1 or 2, R1-R4 are hydrogen atom or the like, and a-d are 1 or 2, or a pharmaceutically acceptable salt thereof, which has an antitumor effect by inhibiting the binding between a MLL fusion protein that is infused with AF4, AF9, or the like, which is a representative fusion partner gene causing MLL leukemia, and menin.

Absstract of: US2022288066A1

Provided herein is a combination comprising an HDAC inhibitor and an IMiD for increasing interferon regulated gene expression or decreasing c-MYC gene expression in a cancer cell or tumor in a subject in need thereof. Increasing interferon regulated gene expression may result in increased recognition of tumors by innate or adaptive immune system and an increase in programmed cell death (apoptosis) gene expression, increasing apoptosis in cancer cells and tumors. The cells can be multiple myeloma cells or diffuse large B-cell lymphoma cells. Also provided are methods for treating myelodysplastic syndromes/acute myeloid leukemia (MDS/AML) or pathogen infections in a subject in need thereof comprising administering to the subject an effective amount of HDAC inhibitor and an IMiD. The HDAC inhibitor can be an HDAC6-selective inhibitor.

Absstract of: US2022288063A1

The present invention relates to lysine deficient protein kinase 1 (WNK1) inhibitors for use in treating patients with blood cancers, in particular leukemia and multiple myeloma.